Disease-Specific Quality-of-Life Assessment

The Phase V® Outcomes Information System focuses on measuring the effects of treatments, therapies and programs on health outcomes. 

Phase V has always recognized the importance of evaluative measurement instruments.  Evaluative measures are designed to have the precision, specificity and sensitivity to be able to detect improvements in health functioning within groups of individuals who have common diseases and conditions.  Long before the distinction among generic and disease-specific instruments was made, Phase V utilized a battery of scales approach to assessment by combining modules of assessment that applied both generally to health functioning and specifically to the concerns and needs of individual with similar conditions and diseases.  As such, the content, metrics and scaling has always provided the ability to differentiate among different therapeutic regimens which had varying impact on health functioning meaningful to the individual.


Quality of Life and Clinical Trials — the first disease-specific studies in hypertension
In the mid 1980’s, one of the very first therapeutic quality-of-life studies conducted at the University of Connecticut School of Medicine was published in the New England Journal of Medicine.  Dr.  Marcia Testa was the statistician and Co-Investigator.  The study demonstrated the quality-of-life differences among three different classes of antihypertension agents which were shown to be comparable with regard to efficacy. A series of publications demonstrated that the negative side effects of antihypertensive medicines had a far reaching impact on patient-reported quality of life. 
(Croog, Levine and Testa, et al, NEJM1986; Testa, Br J Clin Pharmacol, 1987; Williams, Croog, Levine, Testa & Sudilovsky, 1987; Croog, Sudilovsky, Levine & Testa, 1987; Testa, J Hypertens, 1987; Levine, Croog, Sudilovsky & Testa, J Fam Pract, 1987).

Recognizing the importance of the information technologies used in this landmark study, in August, 1987, Phase V Technologies, Inc. was funded as a venture of the University of Connecticut Research and Development Corporation. 


By utilizing its modular patient-reported outcomes approach to disease specific assessment Phase V can detect treatment differentials that are missed by other approaches which rely on generic instuments such as the SF-36, SF-12 and utility measures. These generic and utility instruments and indices were not developed to detect longitudinal changes and differences due to intervention. Rather they were developed to describe health status differences cross-sectionally. The Phase V® Outcomes Systems has been used extensively in clinical trials with the sole purposes of estimating changes over time due to therapeutic differences, including the diseases and conditions cited below:

  • Cancer
  • HIV
  • HIV-Related Wasting
  • HIV-Related Lipodystrophy
  • Diabetes
  • Asthma
  • Depression
  • Sleep Disturbance
  • Benigh Prostatic Hypertrophy
  • Obesity
  • Urinary Incontinence
  • Migraine
  • Pain
  • Rheumatoid Arthritis
  • COPD
  • Hypertension
Insomnia and Sleep Disorders
Migraine Pain



Are You Ready To Be Success With Us ?

We are pleased to receive questions, comments and suggestions. If you ask for a specific piece of information or a reply, we will respond as soon as possible; however, please be patient as we do receive a lot of correspondence.